Citadel Advisors’s Biomerica BMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,025
Closed -$13.7K 12627
2025
Q1
$13.7K Buy
3,025
+112
+4% +$554 ﹤0.01% 13392
2024
Q4
$6.99K Sell
2,913
-3,800
-57% -$10K ﹤0.01% 13767
2024
Q3
$17.6K Buy
+6,713
New +$19.2K ﹤0.01% 12876
2024
Q2
Sell
-100
Closed -$666 14280
2024
Q1
$666 Buy
+100
New +$812 ﹤0.01% 14278
2023
Q3
Sell
-88
Closed -$952 14304
2023
Q2
$952 Hold
88
﹤0.01% 14014
2023
Q1
$1.31K Sell
88
-812
-90% -$17.5K ﹤0.01% 14329
2022
Q4
$24.1K Sell
900
-838
-48% -$24.1K ﹤0.01% 12983
2022
Q3
$55K Buy
+1,738
New +$45K ﹤0.01% 11550
2022
Q2
Sell
-3,313
Closed -$118K 12902
2022
Q1
$118K Sell
3,313
-1,075
-24% -$35.7K ﹤0.01% 12097
2021
Q4
$137K Buy
4,388
+225
+5% +$8.66K ﹤0.01% 12380
2021
Q3
$150K Buy
4,163
+775
+23% +$25.5K ﹤0.01% 12378
2021
Q2
$109K Sell
3,388
-350
-9% -$11.9K ﹤0.01% 12842
2021
Q1
$163K Buy
+3,738
New +$192K ﹤0.01% 11945
2020
Q4
Sell
-1,388
Closed -$77K 10914
2020
Q3
$77K Buy
+1,388
New +$89.8K ﹤0.01% 9412

Other funds holding BMRA

Citadel Advisors's BMRA Position: Q2 2024 in Review

Citadel Advisors sold out of Biomerica (BMRA) in Q2 2024, closing a stake of 4,423 shares — an estimated $29.4K sold.

Citadel Advisors first reported a position in BMRA in Q1 2019 and held it in 9 quarters. The position peaked at $155K in Q4 2022. 35 funds tracked by Wall St. Rank hold BMRA as of Q2 2024.

  • Citadel Advisors reported no remaining Biomerica position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 4,423 Biomerica shares in Q2 2024, an estimated $29.4K.
  • Citadel Advisors first reported a position in Biomerica in Q1 2019 and held it in 9 quarters.
  • Citadel Advisors's Biomerica position peaked at $155K in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Biomerica as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.